TransMedics Group Inc (TMDX)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 35,464 | 32,638 | 3,000 | -10,195 | -25,028 | -35,779 | -17,783 | -28,305 | -36,231 | -42,179 | -47,715 | -46,860 | -44,215 | -37,858 | -29,984 | -27,813 | -28,748 | -31,614 | -34,806 | -35,504 |
| Total stockholders’ equity | US$ in thousands | 228,603 | 209,920 | 189,894 | 159,471 | 137,202 | 126,460 | 145,213 | 192,625 | 187,375 | 187,857 | 50,919 | 59,910 | 67,854 | 78,549 | 88,983 | 97,675 | 103,891 | 109,550 | 113,760 | 46,683 |
| ROE | 15.51% | 15.55% | 1.58% | -6.39% | -18.24% | -28.29% | -12.25% | -14.69% | -19.34% | -22.45% | -93.71% | -78.22% | -65.16% | -48.20% | -33.70% | -28.48% | -27.67% | -28.86% | -30.60% | -76.05% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $35,464K ÷ $228,603K
= 15.51%
TransMedics Group Inc experienced a significant improvement in its return on equity (ROE) from March 2024 to December 2024. The ROE, which was negative for several quarters, jumped from -6.39% in March 2024 to a positive 15.51% by December 2024. This positive trend indicates that the company's profitability and efficiency in generating returns for its shareholders improved notably during this period. It is crucial for investors to monitor this trend to assess the company's financial health and its ability to create value for its shareholders.
Peer comparison
Dec 31, 2024
Company name
Symbol
ROE
TransMedics Group Inc
TMDX
15.51%
BioLife Solutions Inc
BLFS
-5.78%
CONMED Corporation
CNMD
13.76%
LivaNova PLC
LIVN
4.79%
Masimo Corporation
MASI
-28.99%
Medtronic PLC
MDT
8.63%